STEMCELL Technologies Canada Inc.
$49,900,000.00 CAD
- Program
- SIF Stream2- Growth
- Recipient country
- Canada
- Fiscal year
- 2024-2025
- Agreement period
- March 7, 2025 – July 1, 2050
- Reference
- ic:033-2024-2025-Q4-819532
Published purpose
These two biomanufacturing Good Manufacturing Practices (GMP) facilities will be established to enable the production of essential Messenger Ribonucleic Acid (mRNA) vaccines, viral diagnostics and antibody therapeutic inputs at a large scale of up to 5000 litres per batch.
In plain English AI-generated
Funding supports the establishment of two biomanufacturing GMP facilities in Canada to produce mRNA vaccines, viral diagnostics, and antibody therapeutic inputs at large scale.
Category: Health Primarily funds activity in Canada
Based on the published description. See how AI categorization works — the linked official record is authoritative.
Community tags
Tags are applied by readers, not by this site. One tag per person per record.